Genenta Science SpA ADR Cash Flow Conversion Efficiency
Genenta Science SpA ADR cash flow conversion efficiency. Based on the latest financial reports, Genenta Science SpA ADR (GNTA) has a cash flow conversion efficiency ratio of -0.077x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.69 Million) by net assets ($21.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genenta Science SpA ADR (2019–2025)
Cash flow conversion efficiency of Genenta Science SpA ADR from 2019 to 2025. This chart illustrates how Genenta Science SpA ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GNTA stock price for real-time trading data and today's change.
Genenta Science SpA ADR Cash Flow Conversion Ratio Explained
Genenta Science SpA ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genenta Science SpA ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genenta Science SpA ADR ranked by their cash flow conversion efficiency. Also see GNTA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Raytech Holding Limited Ordinary Shares
NASDAQ:RAY
|
-0.125x |
|
Neuphoria Therapeutics Inc
NASDAQ:NEUP
|
0.048x |
|
MetaLabs Co Ltd
KO:090370
|
0.007x |
|
Y&G Corp Bhd
KLSE:7003
|
0.094x |
|
Enzo Biochem Inc
NYSE:ENZ
|
-0.074x |
|
BR.SCH.ED.HLD.SP.ADR CL.A
F:BSK0
|
N/A |
|
MOUNTAIN VALLEY MD HLDGS
F:20MP
|
N/A |
|
Watos Corea Co. Ltd
KQ:079000
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Genenta Science SpA ADR (2019–2025)
The table below shows the annual cash flow conversion efficiency of Genenta Science SpA ADR from 2019 to 2025. Review Genenta Science SpA ADR leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $21.84 Million | $-6.87 Million | -0.314x | +37.03% |
| 2024-12-31 | $12.50 Million | $-6.24 Million | -0.499x | +8.94% |
| 2023-12-31 | $20.43 Million | $-11.21 Million | -0.548x | -130.19% |
| 2022-12-31 | $31.14 Million | $-7.42 Million | -0.238x | -33.05% |
| 2021-12-31 | $38.86 Million | $-6.96 Million | -0.179x | +55.12% |
| 2020-12-31 | $15.15 Million | $-6.04 Million | -0.399x | -202.01% |
| 2019-12-31 | $18.85 Million | $-2.49 Million | -0.132x | -- |
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more